Rituximab (Rituxan/MabThera): the first decade (1993-2003).
about
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanismsSpecificity in cancer immunotherapy.Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCProduction of therapeutic antibodies with controlled fucosylation.Treatment of membranous nephropathy: time for a paradigm shift.Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis.The ODAC Chronicles: part 7. Tale of two goals.
P2860
Q33410392-8A96EC18-490B-488E-BA57-E3BA39FF5B4BQ34574834-FE1D9C30-0DBC-4056-8916-EEAEB1E9829EQ36036378-40B66B80-E832-4688-B3BC-66996C8F3D8FQ36800456-DFCCD499-2091-4C51-9A4E-FB90A5E5330AQ37236636-3970FFD1-F955-47B5-8CDD-2171D51EE355Q37269115-020D303E-F490-4F81-B8E3-F37D09F6BE27Q37323537-F21F586C-6279-4D96-8DC8-1DAD3C687533Q37403194-8C42A6AF-5E1C-465F-8033-45B887EB03DCQ37672128-C1BD6B40-D7BE-41A3-9593-F9B69995D8AAQ39410091-1D91968D-3D9F-44A3-8856-6398DA1DE095Q39665991-CF7B6374-926A-4478-8956-BACCD0A73575Q47754080-3F9B15BC-47BE-4552-857F-9B0FCCD823F8Q48464903-28007BA4-841A-405E-899C-8F3AF66FDCE8
P2860
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@ast
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@en
type
label
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@ast
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@en
prefLabel
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@ast
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@en
P2860
P356
P1476
Rituximab (Rituxan/MabThera): the first decade (1993-2003).
@en
P2093
Antonio J Grillo-López
P2860
P304
P356
10.1586/14737140.3.6.767
P577
2003-12-01T00:00:00Z